- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04391595
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
March 25, 2024 updated by: Nader Sanai
A Phase 0/2 Study of LY3214996 (ERK Inhibitor) in Combination With Abemaciclib (CDK4 and 6 Inhibitor) in Recurrent Glioblastoma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection.
In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial.
Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor.
If positive PK results are demonstrated in ≥50% of Phase 0 participants and at least 5 participants are enrolled into Phase 2, up to approximately 40 additional participants will be enrolled in the dose expansion cohort in order to achieve a total of 25 participants enrolled into Phase 2 (lead-in cohort + dose expansion).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Phase 0 Navigator
- Phone Number: 602-406-8605
- Email: research@ivybraintumorcenter.org
Study Locations
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Recruiting
- Chandler Regional Medical Center
-
Principal Investigator:
- Kaith Almefty, MD
-
Contact:
- Navigator
- Phone Number: 602-406-8605
- Email: research@ivybraintumorcenter.org
-
Phoenix, Arizona, United States, 85013
- Recruiting
- St. Joseph's Hospital and Medical Center
-
Contact:
- Navigator
- Phone Number: 602-406-8605
- Email: research@ivybraintumorcenter.org
-
Principal Investigator:
- Nader Sanai, MD
-
Scottsdale, Arizona, United States, 85251
- Recruiting
- HonorHealth Scottsdale Osborn Medical Center
-
Contact:
- Angelina Cooper
- Phone Number: 4 480-882-5566
- Email: ancooper@honorhealth.com
-
Principal Investigator:
- John Wanebo, MD
-
Contact:
- Phase 0 Navigator
- Phone Number: 602-406-8605
- Email: research@ivybraintumorcenter.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Prior resection of histologically diagnosed WHO Grade IV glioma defined as glioma participants who have progressed on or following standard (Stupp regimen) therapy, which included maximal surgical resection, temozolomide, and fractionated radiotherapy.
- Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI.
- Participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria.
- Sufficient archival tissue available to confirm eligibility.
- For gliomas, archival tissue must demonstrate: (a) RB positivity (≥20%) on immunohistochemistry (IHC); or, no RB mutations on next-generation sequencing (NGS), (b) Chromosomal loss of CDKN2A/B/C; or, CDK4/6 amplification on array CGH or NGS, (c) pERK positivity (>30%) on IHC.
- Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable).
- Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures.
- Age ≥18 at time of consent
- Have a performance status (PS) ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982)
- Ability to swallow oral medications.
Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):
Adequate bone marrow function:
- absolute neutrophil count ≥1,000/mcL
- platelets (at time of surgery) ≥100,000/mcL
- hemoglobin ≥8.0 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.
Adequate hepatic function:
- total bilirubin ≤1.5 X ULN Participants with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.
- AST(SGOT) ≤3 X institutional ULN
- ALT(SGPT) ≤3 X institutional ULN
- Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause.
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 months after the end of treatment administration.
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 6 months after the end of treatment administration.
- Agreement to adhere to Lifestyle Considerations throughout study duration
- Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A washout period of at least 21 days is required between last chemotherapy dose and Day 1 (provided the patient did not receive radiotherapy).
- Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and Day 1.
Exclusion Criteria:
- Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.
- Pregnancy or lactation.
- Known allergic reactions to components of the abemaciclib or LY3214996.
- Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1.
- Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis.
- Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
- Have history of central or branch retinal artery or venous occlusion with significant vision loss or other retinal diseases that cause current visual impairment or would likely cause visual impairment over the time period of the study.
- Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
- Prior therapy with any CDK4/6 inhibitor or any ERK1/2 inhibitor. Prior therapy is defined as a therapeutic dosing.
- Treatment with another investigational drug or other intervention within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
- Have a mean QT interval corrected for heart rate (QTc) of ≥470 milliseconds on screening electrocardiogram (ECG) as calculated using the Bazett's formula.
- The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection.
On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
|
100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection.
Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection.
Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 0: Pharmacokinetic analysis of tumor tissue
Time Frame: 8 hour
|
Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in enhancing and non-enhancing tumor tissue
|
8 hour
|
Phase 0: Pharmacokinetic analysis of cerebrospinal fluid (CSF)
Time Frame: 8 hour
|
Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in CSF
|
8 hour
|
Pharmacokinetic analysis of plasma
Time Frame: Day 6 at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose
|
Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in plasma
|
Day 6 at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose
|
Phase 2: Progression-free survival
Time Frame: up to 60 months
|
Phase 2: 6-month progression-free survival (PFS6) rate measured from time of surgery to date of recurrence
|
up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events
Time Frame: up to 30 days after the last study dose
|
Number of Adverse Events
|
up to 30 days after the last study dose
|
Incidence of drug-related toxicity
Time Frame: up to 30 days after the last study dose
|
Drug-related toxicity
|
up to 30 days after the last study dose
|
Incidence of treatment-emergent adverse events
Time Frame: up to 30 days after the last study dose
|
Treatment-emergent adverse events
|
up to 30 days after the last study dose
|
Phase 0: PD Analysis
Time Frame: Intraoperatively
|
Phase 0: percentage of pRSK+, pERK+, pRB+, pFOXM1, MIB-1+ and Cleaved Caspase 3+ cells from the surgical tissue will be quantified and compared to baseline archival tissue.
|
Intraoperatively
|
Deaths
Time Frame: up to 60 months
|
Deaths
|
up to 60 months
|
Incidence of clinical laboratory abnormalities per CTCAE
Time Frame: up to 30 days after the last study dose
|
Clinical laboratory abnormalities per CTCAE
|
up to 30 days after the last study dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nader Sanai, MD, Deputy Director of the Ivy Brain Tumor Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 8, 2020
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
May 12, 2020
First Submitted That Met QC Criteria
May 12, 2020
First Posted (Actual)
May 18, 2020
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 25, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on Abemaciclib
-
University of ArizonaGeorge Washington UniversityRecruiting
-
Weill Medical College of Cornell UniversityEli Lilly and CompanyRecruitingBladder CancerUnited States
-
Nader SanaiEli Lilly and Company; Barrow Neurological Institute; Ivy Brain Tumor CenterNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterEli Lilly and CompanyActive, not recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisCompleted
-
Medical College of WisconsinRecruitingSoft Tissue Sarcoma | Osteosarcoma | ChondrosarcomaUnited States
-
Eli Lilly and CompanyCompletedHealthyUnited States
-
Eli Lilly and CompanyCompleted
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
Case Comprehensive Cancer CenterRecruitingSmall-cell Lung Cancer | Large Cell Neuroendocrine Carcinoma of the Lung | Extrapulmonary Small Cell CarcinomaUnited States